Live feed10:00:00·1372dPRReleasevia QuantisnowImmunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 CongressByQuantisnow·Wall Street's wire, on your screen.IMCR· Immunocore Holdings plcHealth Care
